Cytyc — NASDAQ 19th Investor Program (June 2007)
40 slides from Cytyc's conference presentation, Jun 19, 2007
Slide 1: Leading Provider of Innovative Medical Technology
A Leading Provider of Innovative Medical Technology NASDAQ 19 th Investor Program June 19, 2007
Slide 2: Disclaimer Regarding Forward-Looking Statements
Disclaimer Regarding Forward-Looking Statements Forward-Looking Statements Regarding Cytyc Investors are cautioned that statements in this presentation which are not strictly historical statements, including, without limitation, Cytyc's future financial condition, operating results and economic perf
Slide 3: Disclaimer Regarding Forward-Looking Statements (continued)
Disclaimer Regarding Forward-Looking Statements (continued) financial statements for the period 1996 through 2002, relating to certain employee stock option exercises, including the impact of the expected any regulatory review or litigation relating to such matters, the impact of new accounting requ
Slide 4: Disclaimer Regarding Forward-Looking Statements (continued)
Disclaimer Regarding Forward-Looking Statements (continued) Forward-Looking Statements Regarding the Proposed Hologic-Cytyc Transaction This presentation also includes forward-looking statements about the timing of the completion of the transaction, the anticipated benefits of the business combinati
Slide 5: Disclaimer Regarding Forward-Looking Statements (continued)
Disclaimer Regarding Forward-Looking Statements (continued) significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies, including third-p
Slide 6: Important Information for Investors and Stockholders
Important Information for Investors and Stockholders Hologic and Cytyc will file a joint proxy statement/prospectus with the SEC in connection with the proposed merger. HOLOGIC AND CYTYC URGE INVESTORS AND STOCKHOLDERS TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OT
Slide 7: Participants in the Solicitation
Participants in the Solicitation Hologic, and certain of its directors and executive officers, may be deemed participants in the solicitation of proxies from the stockholders of Hologic in connection with the merger. The names of Hologic’s directors and executive officers and a description of their
Slide 8: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures "adjusted EPS" and “EBITDA”. Adjusted EPS excludes the write-off and amortization of acquisition-related intang
Slide 9: Growth Objectives and Strategy
Growth Objectives and Strategy Growth Objectives and Strategy Deliver 20+% long-term earnings growth through: Global organic growth across divisions Internal research and development Strategic acquisitions and partnerships Grow existing businesses resulting in continued revenue growth and improved P
Slide 10: Growth through Diversification
1 Billion Growth through Diversification Growth through Diversification 2003 2005 2006 Diagnostic International Surgical $303 Millions $ $508 $608 10% 90% 61% 29% 10% 11% 34% 55% 73% 16% 11% 2004 $394
Slide 11: Operating Divisions
Operating Divisions Operating Divisions Domestic Surgical Products Division NovaSure ® Endometrial Ablation MammoSite ® Radiation Therapy Adiana Helica Domestic Diagnostic Products Division ThinPrep ® Pap Test ThinPrep ® Imaging System Cellient ™ Automated Cell Block System Full Term ® : The Fetal F
Slide 12: Surgical Products
A Leading Provider of Innovative Medical Technology Surgical Products
Slide 13: NovaSure
NovaSure Procedure 4-minute, outpatient procedure No pretreatment drugs required Conscious sedation Recovery = 1 hour Highest success rates Reimbursement established nationwide
Slide 14: Endometrial Ablation: A Large and Underserved Market
Endometrial Ablation: A Large and Underserved Market Endometrial Ablation: A Large and Underserved Market Estimates per Cytyc Corporation *All age groups Hysterectomy, D&C, GEA Total Suffering Silent Sufferers Hormonal Therapy 7m 4.5m 1.8m 0.7m 1 in 5 women suffers from Abnormal Uterine Bleeding 2.5
Slide 15: NovaSure's Competitive Advantage
3.5 39.3 Lupron Yes 10-12 24 Lupron Single Yes 8 26.4 Lupron Double Yes 10 27.4 D&C Yes NovaSure’s Competitive Advantage 1.4 4.2 None No NovaSure RadioFrequency Microsulis Microwave AMS Her Option Cryotherapy BSC HTA Hot water J&J Therma Choice Hot water Treatment Time* Procedure Time* Pre-Treatment
Slide 16: GEA Market Opportunity
GEA Market Opportunity 2006 NovaSure Market Share and Total Procedure Potential GEA Market Opportunity 2006 NovaSure Market Share and Total Procedure Potential NS Share = 62%* NS Share = 9% NS Share = 3% * Note:US NovaSure dollar share equals 69% 1,000,000 2,000,000 3,000,000 4,000,000 5,000,000 6,0
Slide 17: MammoSite Radiation Therapy
MammoSite Radiation Therapy MammoSite Radiation Therapy Creating new standard of care Deliver optimal dose of radiation to tissue at highest risk of cancer recurrence Minimize damage to healthy tissue Expanding data supports partial breast radiation and MammoSite Clinical trial (5-year data; 43 pati
Slide 18: MammoSite Market Opportunity
50,000 100,000 150,000 200,000 250,000 300,000 MammoSite Market Opportunity 275,221 189,490 131,695 126,002 MammoSite Primary U.S. Cases of Breast Cancer and DCIS (.4% Incidence, 40+) Patients Eligible for Breast Conserving Therapy (Excludes >3cm, Size A) Patients Receiving Breast Conserving Therapy
Slide 19: Hysteroscopic Sterilization -- Adiana
Hysteroscopic Sterilization -- Adiana Hysteroscopic Sterilization -- Adiana Alternative to tubal ligation Radiofrequency generator One-time-use delivery catheter FDA process underway Complementary to NovaSure Endometrial Ablation System $1 billion U.S. market opportunity Reimbursement established
Slide 20: Cytyc Surgical Products - Summary
Cytyc Surgical Products - Summary Cytyc Surgical Products - Summary Changing medical practice with products that address potential US markets > $5B NovaSure best-in-class product addressing a $2.5B market NovaSure Elective use > $1B MammoSite creating a new standard of care with $300MM US opportunit
Slide 21: Diagnostic Products
A Leading Provider of Innovative Medical Technology Diagnostic Products
Slide 22: Domestic Diagnostic Products
Domestic Diagnostic Products Domestic Diagnostic Products ThinPrep ® Pap Test ThinPrep ® Imaging System FullTerm ® : The Fetal Fibronectin Test Cellient ™ Automated Cell Block System
Slide 23: ThinPrep System Advantages
Since ThinPrep introduction in 1996, estimated number of cervical cancer cases in the US decreased 28% ThinPrep System Advantages ThinPrep System Advantages Superiority to Conventional Pap ThinPrep Imaging System ThinPrep Pap Test Market Share (%) Estimated New Cases (1,000) HPV FDA approved CT/NG F
Slide 24: ThinPrep Imaging System
ThinPrep Imaging System ThinPrep Imaging System Advanced computerized imaging Dual screening approach Improves accuracy Improves lab economics Increases reimbursement Decreases labor costs Improves workflow Protects ThinPrep market share Significant increase in HSIL
Slide 25: ThinPrep Imaging System: Becoming the Standard of Care
ThinPrep Imaging System: Becoming the Standard of Care ThinPrep Imaging System: Becoming the Standard of Care Notes: Imaging started in Q2 of 2003 Percent Slides Imaged 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% Q4 2003 Q4 2004 Q4 2005 Q4 2006 1% 13% 30% 40%
Slide 26: Cellient Automated Cell Block System
Cellient ™ Automated Cell Block System Cellient ™ Automated Cell Block System Allows individual cells or small tissue samples (<2mm diameter) to be processed for histological examination Eliminates operator dependence Provides standardized, consistent preparations in less than one hour, and ensures
Slide 27: FullTerm: The Fetal Fibronectin Test
Full Term: The Fetal Fibronectin Test Full Term: The Fetal Fibronectin Test Identifies women at risk of preterm birth FDA approved Reimbursement established Market opportunity: $500 million worldwide
Slide 28: Domestic Diagnostic Products - Summary
Domestic Diagnostic Products - Summary Domestic Diagnostic Products - Summary ThinPrep ® Pap Test Leading test for cervical cancer screening US opportunity: 50-55 million tests annually International: >100 million tests 250 million tests since approval Platform technology ThinPrep ® Imaging System A
Slide 29: International
A Leading Provider of Innovative Medical Technology International
Slide 30: Cytyc International – Driving Growth Worldwide
Operating in over 20 countries Marlborough Cytyc International – Driving Growth Worldwide Legend Australia UK Spain France Italy Germany Switzerland Hong Kong Costa Rica China Mexico Brazil South Africa So. Korea Company presence Key distributors Japan Canada
Slide 31: International Revenue 2004 – 2006
International Revenue 2004 – 2006 International Revenue 2004 – 2006 10000 20000 30000 40000 50000 60000 70000 80000 2004 2005 2006 ROW AsiaPac Europe Total CAGR 30% $40m $52m $68m
Slide 32: Global ThinPrep Market Opportunity
Less than 10% market penetration worldwide Europe Asia - Pacific Rest of World Total: $500+ million annual revenue opportunity Additional upside from Imager Tests (Millions) Global ThinPrep Market Opportunity
Slide 33: Creating a Global Leader in Women's Healthcare
Creating a Global Leader in Women’s Healthcare Continuing a legacy of leading technology, innovation and rapid growth May 21, 2007
Slide 34: Strategic Rationale Combined Strengths
Strategic Rationale Combined Strengths Expanded Product Portfolio Comprehensive Sales Coverage Ability to Leverage OB/GYN Channel Significant Cross-Selling Synergies Enhanced International Presence Creating a Global Leader in Women’s Healthcare Market Share Leader in Major Product Lines Proven Manag
Slide 35: Comprehensive Women's Healthcare Platform
MultiCare Stereotactic Biopsy Discovery Osteoporosis Screening Selenia Breast Cancer Screening MammoSite Radiation Therapy ThinPrep Pap Test & Imaging System Cervical Cancer Screening NovaSure Endometrial Ablation Adiana Contraception FullTerm - Adeza Preterm Labor Best-in-Class Solutions in Women’s
Slide 36: Solutions for Major Women's Healthcare Issues
Solutions for Major Women’s Healthcare Issues Helica Unpenetrated 1 in 3 Gestiva International ThinPrep Imaging System International Tomosynthesis Suros Celero Additional Opportunities Adiana FullTerm Fetal Fibronectin Discovery Sahara NovaSure ThinPrep Pap Test Selenia MultiCare Suros ATEC MammoSit
Slide 37: Financial Rationale
Multiple platforms to enhance top and bottom line growth Increased scale through diversification of revenue and strong margin profile Enhanced cash flow; LQA EBITDA of ~$436M Revenue and cost synergy opportunities Estimated more than $0.10 accretive to adjusted EPS within the first full year after c
Slide 38: Combined Financial Strength
Combined Financial Strength 46% Gross Margin $161M EBITDA $724M Revenue LQA Hologic 75% Gross Margin $275M EBITDA $720M Revenue LQA Cytyc 60% Gross Margin $436M EBITDA $1.44B Revenue LQA Combined Company
Slide 39: Creating a Global Leader in Women's Healthcare
Creating a Global Leader in Women’s Healthcare Comprehensive Women’s Healthcare Product Portfolio – Complementary best-in-class technologies Expanded Commercial Capabilities – Expansive U.S. sales channel coverage – Enhanced presence in key international markets – Platform for entry into new markets
Slide 40: Leading Provider of Innovative Medical Technology
A Leading Provider of Innovative Medical Technology